S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:ATRI

Atrion Stock Forecast, Price & News

$735.20
-26.30 (-3.45%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$735.20
$765.00
50-Day Range
$674.81
$802.00
52-Week Range
$571.17
$805.62
Volume
4,398 shs
Average Volume
6,656 shs
Market Capitalization
$1.32 billion
P/E Ratio
41.54
Dividend Yield
1.02%
Beta
0.09
30 days | 90 days | 365 days | Advanced Chart
Receive ATRI News and Ratings via Email

Sign-up to receive the latest news and ratings for Atrion and its competitors with MarketBeat's FREE daily newsletter.


Atrion logo

About Atrion

Atrion Corp. engages in the manufacture and development of products for medical applications. It offers products fro cardiovascular, fluid delivery, and ophthalmic. It also offers contract manufacturing & kitting services; and marine & aviation inflation components. The company was founded in 1944 and is headquartered in Allen, TX.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:ATRI
CUSIP
04990410
Employees
636
Year Founded
N/A

Sales & Book Value

Annual Sales
$147.59 million
Cash Flow
$22.78 per share
Book Value
$132.88 per share

Profitability

Net Income
$32.12 million
Pretax Margin
24.06%

Debt

Price-To-Earnings

Miscellaneous

Free Float
1,404,000
Market Cap
$1.32 billion
Optionable
Not Optionable

Company Calendar

Ex-Dividend
9/14/2021
Dividend Payable
9/30/2021
Last Earnings
11/08/2021
Today
11/27/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/25/2022

MarketRank

Overall MarketRank

2.13 out of 5 stars

Medical Sector

438th out of 1,392 stocks

Surgical & Medical Instruments Industry

41st out of 125 stocks

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 3.3Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












Atrion (NASDAQ:ATRI) Frequently Asked Questions

How has Atrion's stock price been impacted by COVID-19?

Atrion's stock was trading at $667.00 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ATRI stock has increased by 10.2% and is now trading at $735.20.
View which stocks have been most impacted by COVID-19
.

When is Atrion's next earnings date?

Atrion is scheduled to release its next quarterly earnings announcement on Friday, February 25th 2022.
View our earnings forecast for Atrion
.

How were Atrion's earnings last quarter?

Atrion Co. (NASDAQ:ATRI) announced its quarterly earnings data on Monday, November, 8th. The medical instruments supplier reported $4.58 earnings per share for the quarter. The medical instruments supplier had revenue of $42.86 million for the quarter. Atrion had a trailing twelve-month return on equity of 13.39% and a net margin of 20.58%.
View Atrion's earnings history
.

How often does Atrion pay dividends? What is the dividend yield for Atrion?

Atrion declared a quarterly dividend on Friday, November 12th. Stockholders of record on Wednesday, December 1st will be paid a dividend of $1.95 per share on Wednesday, December 15th. This represents a $7.80 dividend on an annualized basis and a dividend yield of 1.06%. The ex-dividend date is Tuesday, November 30th.
View Atrion's dividend history
.

Is Atrion a good dividend stock?

Atrion pays an annual dividend of $7.80 per share and currently has a dividend yield of 1.02%. Atrion has been increasing its dividend for 19 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Atrion is 44.07%. This payout ratio is at a healthy, sustainable level, below 75%.
View Atrion's dividend history.

Who are Atrion's key executives?

Atrion's management team includes the following people:
  • David A. Battat, President & Chief Executive Officer
  • Jeffery Strickland, Chief Financial Officer, Secretary, Treasurer & VP

What is David A. Batta's approval rating as Atrion's CEO?

1 employees have rated Atrion CEO David A. Batta on Glassdoor.com. David A. Batta has an approval rating of 100% among Atrion's employees. This puts David A. Batta in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Atrion own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atrion investors own include International Paper (IP), AT&T (T), WestRock (WRK), AbbVie (ABBV), Caterpillar (CAT), Eastman Chemical (EMN), Gilead Sciences (GILD), Altria Group (MO), Pfizer (PFE) and Philip Morris International (PM).

What is Atrion's stock symbol?

Atrion trades on the NASDAQ under the ticker symbol "ATRI."

Who are Atrion's major shareholders?

Atrion's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Kayne Anderson Rudnick Investment Management LLC (11.03%), Neuberger Berman Group LLC (10.97%), BlackRock Inc. (6.23%), Dimensional Fund Advisors LP (2.93%), Renaissance Technologies LLC (2.47%) and Boston Trust Walden Corp (1.78%). Company insiders that own Atrion stock include Emile A Battat and John P Stupp Jr.
View institutional ownership trends for Atrion
.

Which major investors are selling Atrion stock?

ATRI stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Kayne Anderson Rudnick Investment Management LLC, Renaissance Technologies LLC, Morgan Stanley, Thrivent Financial for Lutherans, Dimensional Fund Advisors LP, New York State Common Retirement Fund, and Nisa Investment Advisors LLC.
View insider buying and selling activity for Atrion
or view top insider-selling stocks.

Which major investors are buying Atrion stock?

ATRI stock was bought by a variety of institutional investors in the last quarter, including Neuberger Berman Group LLC, Boston Trust Walden Corp, Citadel Advisors LLC, Aviva PLC, Moors & Cabot Inc., Millennium Management LLC, Victory Capital Management Inc., and SG Americas Securities LLC.
View insider buying and selling activity for Atrion
or or view top insider-buying stocks.

How do I buy shares of Atrion?

Shares of ATRI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Atrion's stock price today?

One share of ATRI stock can currently be purchased for approximately $735.20.

How much money does Atrion make?

Atrion has a market capitalization of $1.32 billion and generates $147.59 million in revenue each year. The medical instruments supplier earns $32.12 million in net income (profit) each year or $17.70 on an earnings per share basis.

How many employees does Atrion have?

Atrion employs 636 workers across the globe.

What is Atrion's official website?

The official website for Atrion is www.atrioncorp.com.

Where are Atrion's headquarters?

Atrion is headquartered at ONE ALLENTOWN PARKWAY, ALLEN TX, 75002.

How can I contact Atrion?

Atrion's mailing address is ONE ALLENTOWN PARKWAY, ALLEN TX, 75002. The medical instruments supplier can be reached via phone at (972) 390-9800, via email at [email protected], or via fax at 972-396-7581.


This page was last updated on 11/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.